Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 16, 2020

SELL
$8.15 - $21.17 $487,215 - $1.27 Million
-59,781 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$21.19 - $40.2 $1.27 Million - $2.4 Million
59,781 New
59,781 $1.28 Million

Others Institutions Holding NXTC

About NextCure, Inc.


  • Ticker NXTC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,748,800
  • Market Cap $33M
  • Description
  • NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...
More about NXTC
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.